JP7365704B2 - 幹細胞へのペイロードの送達 - Google Patents

幹細胞へのペイロードの送達 Download PDF

Info

Publication number
JP7365704B2
JP7365704B2 JP2020534820A JP2020534820A JP7365704B2 JP 7365704 B2 JP7365704 B2 JP 7365704B2 JP 2020534820 A JP2020534820 A JP 2020534820A JP 2020534820 A JP2020534820 A JP 2020534820A JP 7365704 B2 JP7365704 B2 JP 7365704B2
Authority
JP
Japan
Prior art keywords
stem cells
cells
gla
delivery agent
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020534820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533021A (ja
JP2020533021A5 (enExample
Inventor
ハーミストン，テリー
ボーゾン，マキシーン
コンタグ，クリストファー，エイチ．
ハーディ，ジョナサン
ブランケンベルグ，フランシス，ジェラルド
Original Assignee
グラディエーター バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラディエーター バイオサイエンシーズ インコーポレイテッド filed Critical グラディエーター バイオサイエンシーズ インコーポレイテッド
Publication of JP2020533021A publication Critical patent/JP2020533021A/ja
Publication of JP2020533021A5 publication Critical patent/JP2020533021A5/ja
Application granted granted Critical
Publication of JP7365704B2 publication Critical patent/JP7365704B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0631—Mammary cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
JP2020534820A 2017-09-05 2018-09-05 幹細胞へのペイロードの送達 Active JP7365704B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762554533P 2017-09-05 2017-09-05
US201762554530P 2017-09-05 2017-09-05
US62/554,533 2017-09-05
US62/554,530 2017-09-05
US201762569403P 2017-10-06 2017-10-06
US201762569411P 2017-10-06 2017-10-06
US62/569,411 2017-10-06
US62/569,403 2017-10-06
US201762584565P 2017-11-10 2017-11-10
US62/584,565 2017-11-10
US201762593014P 2017-11-30 2017-11-30
US62/593,014 2017-11-30
PCT/US2018/049618 WO2019050997A1 (en) 2017-09-05 2018-09-05 LOAD DISTRIBUTION USEFUL IN STEM CELLS

Publications (3)

Publication Number Publication Date
JP2020533021A JP2020533021A (ja) 2020-11-19
JP2020533021A5 JP2020533021A5 (enExample) 2021-10-14
JP7365704B2 true JP7365704B2 (ja) 2023-10-20

Family

ID=63714024

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020534820A Active JP7365704B2 (ja) 2017-09-05 2018-09-05 幹細胞へのペイロードの送達
JP2020534821A Pending JP2020533404A (ja) 2017-09-05 2018-09-05 細胞内送達法
JP2020512854A Pending JP2020533976A (ja) 2017-09-05 2018-09-05 エキソソームを標的化する方法
JP2024041903A Pending JP2024073589A (ja) 2017-09-05 2024-03-18 エキソソームを標的化する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020534821A Pending JP2020533404A (ja) 2017-09-05 2018-09-05 細胞内送達法
JP2020512854A Pending JP2020533976A (ja) 2017-09-05 2018-09-05 エキソソームを標的化する方法
JP2024041903A Pending JP2024073589A (ja) 2017-09-05 2024-03-18 エキソソームを標的化する方法

Country Status (14)

Country Link
US (3) US11981723B2 (enExample)
EP (3) EP3679127A1 (enExample)
JP (4) JP7365704B2 (enExample)
KR (2) KR20200050961A (enExample)
CN (2) CN111065733A (enExample)
AU (2) AU2018328223A1 (enExample)
BR (2) BR112020004319A2 (enExample)
CA (2) CA3074678A1 (enExample)
IL (2) IL272908A (enExample)
MX (2) MX2020002250A (enExample)
PE (2) PE20201263A1 (enExample)
SG (2) SG11202001535RA (enExample)
WO (3) WO2019050997A1 (enExample)
ZA (2) ZA202000650B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3524618B1 (en) 2013-03-15 2023-03-08 GLAdiator Biosciences, Inc. Gla domains as targeting agents
EP3664830A4 (en) 2017-08-07 2020-07-01 The Regents of the University of California RISK-FREE CELL THERAPEUTIC GENERATION PLATFORM
AU2018328223A1 (en) 2017-09-05 2020-03-12 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN110036976B (zh) * 2019-05-08 2021-12-07 华南农业大学 一种阻断鸡禽白血病病毒垂直传播的方法及其应用
CN110423777A (zh) * 2019-07-23 2019-11-08 河南科技大学 无荧光染料标记外泌体及其制备方法
CN110711249B (zh) * 2019-09-19 2020-10-27 北京化工大学 一种溶酶体膜包覆纳米颗粒的制备方法
AU2020364084A1 (en) * 2019-10-09 2022-04-21 Mayo Foundation For Medical Education And Research Canine distemper virus hemagglutinin and fusion polypeptides
KR102547446B1 (ko) * 2019-11-29 2023-06-26 서울대학교산학협력단 무표지 폴리다이아세틸렌 리포좀 기반의 엑소좀의 검출 방법
CN111803646B (zh) * 2020-06-04 2022-07-05 苏州大学 一种实体肿瘤联合治疗组合物
US20210393536A1 (en) * 2020-06-23 2021-12-23 Board Of Regents, The University Of Texas System Methods and compositions related to extracellular vesicles
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN112516110B (zh) * 2020-10-13 2022-05-13 北京化工大学 一种细胞膜包覆纳米酶的方法
CN112553152B (zh) * 2020-10-27 2024-09-17 重庆市铂而斐细胞生物技术有限公司 一种快速提高脂肪间充质干细胞外泌体产量的方法
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
KR102285160B1 (ko) * 2020-12-24 2021-08-03 주식회사 타임바이오 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물
KR102739746B1 (ko) * 2021-10-25 2024-12-10 인하대학교 산학협력단 바르토넬라 헨셀라이 유래 세포외 소포체를 이용한 바르토넬라 감염증 진단 방법
CN114940967B (zh) * 2022-05-09 2024-05-31 中山大学 母乳细胞外囊泡及其在制备骨修复材料中的应用
TWI872888B (zh) * 2022-12-30 2025-02-11 財團法人工業技術研究院 用於穩定血液中游離核酸及/或外泌體核酸的組成物、含其之試劑與套組以及其用途
CN116421738B (zh) * 2023-02-28 2024-03-19 中国医科大学附属第一医院 捕获抗原的溶瘤病毒及其药物组合与制备和应用
KR20240154736A (ko) * 2023-04-18 2024-10-28 가톨릭대학교 산학협력단 면역관문 억제제의 표적화된 전달을 위한 세포외소포체의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008173034A (ja) 2007-01-17 2008-07-31 Natl Inst Of Radiological Sciences 幹細胞における低線量被ばくの検出マーカー、及び該マーカーを用いる幹細胞での低線量被ばくレベルを推定又は検出する方法
JP2013518108A (ja) 2010-01-26 2013-05-20 アントフロゲネシス コーポレーション 胎盤幹細胞を用いる骨関連癌の治療
JP2014062084A (ja) 2012-09-19 2014-04-10 Georgetown Univ 標的化されたリポソーム
CN105567642A (zh) 2016-02-01 2016-05-11 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法
JP2016513463A (ja) 2013-03-15 2016-05-16 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化剤としてのＧｌａドメイン
US20170224840A1 (en) 2014-08-11 2017-08-10 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Drug Delivery System Comprising A Cancer Stem Cell-Targeted Carbon Nanotube, Preparation and Use Thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
NZ255256A (en) 1992-08-27 1997-02-24 Deakin Res Ltd Synthetic peptide antigen analogues with retro, inverso or retro-inverso modification, their use and antibodies against them
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
AU6985594A (en) 1993-06-30 1995-01-24 Bonno Nammen Bouma Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods
US5597457A (en) 1995-01-23 1997-01-28 The Regents Of The University Of California System and method for forming synthetic protein crystals to determine the conformational structure by crystallography
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP0965597A4 (en) 1996-12-27 2003-01-08 Mochida Pharm Co Ltd CELL MEMBRANE EFFECTIVE DRUGS
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
EP1105523A4 (en) 1998-08-13 2002-09-25 Wyeth Corp ESCHERICHIA COLI GDP-FUCOSE SYNTHETASE CRYSTALLINE STRUCTURE AND METHODS OF USE THEREOF
AU4218799A (en) 1998-08-25 2000-03-14 Scripps Research Institute, The Methods and systems for predicting protein function
US6801860B1 (en) 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2002003407A (ja) 2000-06-20 2002-01-09 Medei Sci Puraningu:Kk ハイドロキシアパタイトカルシウム指向性薬物輸送担体
WO2003017032A2 (en) 2001-08-14 2003-02-27 Dana-Farber Cancer Institute, Inc. Computer-based methods of designing molecules
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
ATE458057T1 (de) 2003-06-19 2010-03-15 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
UA88272C2 (ru) * 2003-08-15 2009-10-12 Борд Оф Трастиз Оф Зе Юниверсити Оф Иллинойс Применение полипептидов семейства купредоксина в лечении рака
EP1744734A2 (en) 2004-02-20 2007-01-24 Novo Nordisk A/S Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ATE491799T1 (de) 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
MX2007001294A (es) 2004-08-17 2008-03-04 Zlb Behring Gmbh Polipeptidos modificados que dependen de vitamina k.
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
KR100987547B1 (ko) * 2006-06-01 2010-10-12 가톨릭대학교 산학협력단 냉동보관된 제대혈 줄기세포로부터 초기 세포사를 측정하는조성물, 키트 및 그 방법
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
BRPI0810172A2 (pt) 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
KR100968839B1 (ko) 2008-02-25 2010-07-09 경북대학교 산학협력단 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010006136A2 (en) * 2008-07-09 2010-01-14 Mayo Foundation For Medical Education And Research Adenovirus targeting
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US8283167B2 (en) 2009-02-11 2012-10-09 Clear Vascular Inc. Preparation of annexin derivatives
WO2010151736A1 (en) 2009-06-25 2010-12-29 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules
WO2012087241A1 (en) 2010-12-20 2012-06-28 Agency For Science, Technology And Research Method of purifying exosomes
WO2012120130A1 (en) 2011-03-09 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods to characterize patients suffering from hemolysis
ES2682750T5 (en) 2011-07-18 2025-02-04 Iba Lifesciences Gmbh Method of reversibly staining a target cell
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
TWI497845B (zh) 2012-07-18 2015-08-21 Murata Manufacturing Co Coaxial connector
CA2879542A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
CN106414503A (zh) * 2014-03-11 2017-02-15 分子模板公司 包含邻近氨基酸端的志贺毒素a亚基效应子区和细胞靶向性免疫球蛋白型结合区的蛋白
CN113831416A (zh) * 2014-06-11 2021-12-24 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
WO2017118764A1 (en) * 2016-01-07 2017-07-13 Thomas Brocker Novel approaches for the in vivo and in vitro visualization of dying cells
AU2018328223A1 (en) 2017-09-05 2020-03-12 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008173034A (ja) 2007-01-17 2008-07-31 Natl Inst Of Radiological Sciences 幹細胞における低線量被ばくの検出マーカー、及び該マーカーを用いる幹細胞での低線量被ばくレベルを推定又は検出する方法
JP2013518108A (ja) 2010-01-26 2013-05-20 アントフロゲネシス コーポレーション 胎盤幹細胞を用いる骨関連癌の治療
JP2014062084A (ja) 2012-09-19 2014-04-10 Georgetown Univ 標的化されたリポソーム
JP2016513463A (ja) 2013-03-15 2016-05-16 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化剤としてのＧｌａドメイン
JP2016516037A (ja) 2013-03-15 2016-06-02 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化剤としてのＧｌａドメイン
US20170224840A1 (en) 2014-08-11 2017-08-10 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Drug Delivery System Comprising A Cancer Stem Cell-Targeted Carbon Nanotube, Preparation and Use Thereof
CN105567642A (zh) 2016-02-01 2016-05-11 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yokoyama, T. et al.，"Immunohistochemical detection of phosphatidylserine and thrombospondin on denucleating erythroblasts in rat bone marrow"，J. Vet. Med. Sci.，2011年，Vol. 73，pp. 949-952

Also Published As

Publication number Publication date
JP2020533404A (ja) 2020-11-19
WO2019051002A1 (en) 2019-03-14
CA3074678A1 (en) 2019-03-14
JP2020533021A (ja) 2020-11-19
CN111051500A (zh) 2020-04-21
ZA202000650B (en) 2021-02-24
WO2019050997A1 (en) 2019-03-14
RU2020107182A (ru) 2021-10-06
EP3679129A1 (en) 2020-07-15
IL272908A (en) 2020-04-30
PE20201263A1 (es) 2020-11-19
US20210062143A1 (en) 2021-03-04
BR112020004319A2 (pt) 2020-09-08
EP3679127A1 (en) 2020-07-15
AU2018328223A1 (en) 2020-03-12
US11981723B2 (en) 2024-05-14
ZA202001012B (en) 2021-03-31
CN111065733A (zh) 2020-04-24
MX2020002250A (es) 2020-09-18
KR20200050975A (ko) 2020-05-12
KR20200050961A (ko) 2020-05-12
SG11202001536PA (en) 2020-03-30
US20200407422A1 (en) 2020-12-31
EP3679128A1 (en) 2020-07-15
IL272942A (en) 2020-04-30
PE20201462A1 (es) 2020-12-17
MX2020002442A (es) 2020-07-13
WO2019050998A1 (en) 2019-03-14
BR112020003945A2 (pt) 2020-09-08
JP2024073589A (ja) 2024-05-29
JP2020533976A (ja) 2020-11-26
RU2020107182A3 (enExample) 2022-02-28
US20200407421A1 (en) 2020-12-31
AU2018330427A1 (en) 2020-04-02
SG11202001535RA (en) 2020-03-30
CA3074291A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
JP7365704B2 (ja) 幹細胞へのペイロードの送達
Leng et al. Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy
EP3261677B1 (en) Targeted transplantation of mitochondria to hepatocytes
JP6739132B2 (ja) がんの診断及び処置のための組成物及び方法
JP2023519867A (ja) 新規無核細胞およびそれらの使用
Liu et al. Quantitative tracking tumor suppression efficiency of human umbilical cord-derived mesenchymal stem cells by bioluminescence imaging in mice hepatoma model
Lee et al. Human adipose tissue stem cells promote the growth of acute lymphoblastic leukemia cells in NOD/SCID mice
Koustoulidou et al. Cancer-associated fibroblasts as players in cancer development and progression and their role in targeted radionuclide imaging and therapy. Cancers (Basel). 2021; 13: 1100
Han et al. The use of normal stem cells and cancer stem cells for potential anti-cancer therapeutic strategy
RU2795155C1 (ru) Доставка полезной нагрузки к стволовым клеткам
Shah Stem cell therapeutics for cancer
RU2781640C2 (ru) Способ адресного воздействия на экзосомы
BR112020024034A2 (pt) composições e métodos para diagnóstico e tratamento de câncer
Zubaľ Fibroblast activation protein in the tumour microenvironment of glioblastoma and brain metastases
Yang et al. Stem Cells and Gastric Cancer
Kerrigan et al. The role of mesenchymal stromal cells in human brain tumors
Okolie Intra-Cavity Stem Cells Target Post-Surgical Brain Tumor Progression In Novel Resection And Recurrence Mouse Models
Parker Cell-mediated Gene Therapy for Liver Disease
Ben-Shoshan et al. Endothelial Progenitor Cells: From Bench to Bedside
Sukowati The cancer stem cells and human liver cancer: identifications, expressions and drug resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231002

R150 Certificate of patent or registration of utility model

Ref document number: 7365704

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150